Literature DB >> 21472489

Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.

Hyunuk Kim1, Juho Lee, Tae Hyung Kim, Eun Seong Lee, Kyung Taek Oh, Don Haeng Lee, Eun-Seok Park, You Han Bae, Kang Choon Lee, Yu Seok Youn.   

Abstract

PURPOSE: To study the development of porous poly(lactic-co-glycolic acid) microparticles (PLGA MPs) coated initially with albumin and then with palmityl-acylated exendin-4 (Pal-Ex4) as an inhalation system for treating diabetes.
METHODS: Porous PLGA MPs were prepared by w/o/w double emulsification using hydroxypropyl-β-cyclodextrin and poly(ethylene-alt-maleic anhydride). Albumin was covalently attached to the MPs using EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide); Pal-Ex4 was then bound on the albumin surface. Albumin-binding degree and aerosolization efficiency were investigated. Deposition of the MPs after insufflations into the lungs of ICR mice was observed by image monitoring, and pulmonary hypoglycemic efficacies were examined in db/db mice. Cytotoxicity and histopathology induced by MPs were examined in Calu-3 and A549 cells and in the lungs of db/db mice, respectively.
RESULTS: Albumin-coating and Pal-Ex4-binding to porous MP were performed with acceptable efficiencies. Pal-Ex4-bound albumin-coated MPs (Pal-Ex4/HSA-PLGA MP) were of high porosity and had appropriate aerodynamic sizes. Furthermore, this MP was efficiently deposited throughout mouse lungs, and exhibited a prolonged hypoglycemia and no significant lung tissue damage in db/db mice.
CONCLUSION: Pal-Ex4/HSA-PLGA MP demonstrated many meaningful pharmaceutical advantages for the treatment of diabetes, in terms of aerosolization efficiency, drug loading, sustained drug-release, and hypoglycemic duration in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472489     DOI: 10.1007/s11095-011-0427-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

Review 1.  The lungs as a portal of entry for systemic drug delivery.

Authors:  John S Patton; C Simone Fishburn; Jeffry G Weers
Journal:  Proc Am Thorac Soc       Date:  2004

Review 2.  Inhaling medicines: delivering drugs to the body through the lungs.

Authors:  John S Patton; Peter R Byron
Journal:  Nat Rev Drug Discov       Date:  2007-01       Impact factor: 84.694

Review 3.  Recent advances in pulmonary drug delivery using large, porous inhaled particles.

Authors:  D A Edwards; A Ben-Jebria; R Langer
Journal:  J Appl Physiol (1985)       Date:  1998-08

Review 4.  Formulation strategy and use of excipients in pulmonary drug delivery.

Authors:  Gabrielle Pilcer; Karim Amighi
Journal:  Int J Pharm       Date:  2010-03-17       Impact factor: 5.875

5.  Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs.

Authors:  Francesca Ungaro; Giuseppe De Rosa; Agnese Miro; Fabiana Quaglia; Maria Immacolata La Rotonda
Journal:  Eur J Pharm Sci       Date:  2006-05-22       Impact factor: 4.384

6.  Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery.

Authors:  Hyun Jung Chung; Hong Kee Kim; Jun Jin Yoon; Tae Gwan Park
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

7.  Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.

Authors:  Kang Choon Lee; Su Young Chae; Tae Hyung Kim; Seulki Lee; Eun Seong Lee; Yu Seok Youn
Journal:  Regul Pept       Date:  2008-10-14

8.  Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.

Authors:  Su Young Chae; Cheng-Hao Jin; Jae Hee Shin; Sohee Son; Tae Hyung Kim; Seulki Lee; Yu Seok Youn; Youngro Byun; Myung-Shik Lee; Kang Choon Lee
Journal:  J Control Release       Date:  2009-11-10       Impact factor: 9.776

9.  Development of highly porous large PLGA microparticles for pulmonary drug delivery.

Authors:  Yan Yang; Nimisha Bajaj; Peisheng Xu; Kimberly Ohn; Michael D Tsifansky; Yoon Yeo
Journal:  Biomaterials       Date:  2009-01-08       Impact factor: 12.479

10.  Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.

Authors:  Francesca Ungaro; Roberta d'Emmanuele di Villa Bianca; Concetta Giovino; Agnese Miro; Raffaella Sorrentino; Fabiana Quaglia; Maria Immacolata La Rotonda
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

View more
  8 in total

1.  Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.

Authors:  Bikash Manandhar; Jung-Mo Ahn
Journal:  J Med Chem       Date:  2014-11-13       Impact factor: 7.446

2.  A signal-amplifiable biochip quantifies extracellular vesicle-associated RNAs for early cancer detection.

Authors:  Jiaming Hu; Yan Sheng; Kwang Joo Kwak; Junfeng Shi; Bohao Yu; L James Lee
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

3.  One-Step Method to Prepare PLLA Porous Microspheres in a High-Voltage Electrostatic Anti-Solvent Process.

Authors:  Ying Wang; Li-Hui Zhu; Ai-Zheng Chen; Qiao Xu; Yu-Juan Hong; Shi-Bin Wang
Journal:  Materials (Basel)       Date:  2016-05-13       Impact factor: 3.623

4.  Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology.

Authors:  Pei-Yao Xu; Ranjith Kumar Kankala; Yu-Jing Pan; Hui Yuan; Shi-Bin Wang; Ai-Zheng Chen
Journal:  Int J Nanomedicine       Date:  2018-08-15

5.  Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.

Authors:  Changkyu Lee; Ji Su Choi; Insoo Kim; Kyung Taek Oh; Eun Seong Lee; Eun-Seok Park; Kang Choon Lee; Yu Seok Youn
Journal:  Int J Nanomedicine       Date:  2013-08-09

Review 6.  Long-acting preparations of exenatide.

Authors:  Yunpeng Cai; Liangming Wei; Liuqing Ma; Xiwen Huang; Anqi Tao; Zhenguo Liu; Weien Yuan
Journal:  Drug Des Devel Ther       Date:  2013-09-05       Impact factor: 4.162

7.  Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics.

Authors:  Junqiu Zhai; Zhanlun Ou; Liuting Zhong; Yu-E Wang; Li-Ping Cao; Shixia Guan
Journal:  Drug Deliv       Date:  2020-11-18       Impact factor: 6.419

8.  Nanomicelle-Microsphere Composite as a Drug Carrier to Improve Lung-Targeting Specificity for Lung Cancer.

Authors:  Qianqian Zhang; Jianwei Bao; Tijie Duan; Minxing Hu; Yuting He; Junwei Wang; Rongfeng Hu; Jihui Tang
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.